Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

IRE1/XBP-1 activation has a major role in Triple negative breast cancer (TNBC). Here, the authors show that inhibition of IRE1’s RNase activity attenuates autocrine and paracrine signaling of pro-tumorigenic cytokines and synergizes with paclitaxel to confer potent anti-tumor effects in TNBC.

Bibliographic Details
Main Authors: Susan E. Logue, Eoghan P. McGrath, Patricia Cleary, Stephanie Greene, Katarzyna Mnich, Aitor Almanza, Eric Chevet, Róisín M. Dwyer, Anup Oommen, Patrick Legembre, Florence Godey, Emma C. Madden, Brian Leuzzi, Joanna Obacz, Qingping Zeng, John B. Patterson, Richard Jäger, Adrienne M. Gorman, Afshin Samali
Format: Article
Language:English
Published: Nature Publishing Group 2018-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-05763-8

Internet

https://doi.org/10.1038/s41467-018-05763-8

Similar Items